Research on Tobacco Heating System (THS) 1

Apr.08.2022
Research on Tobacco Heating System (THS) 1
Research on tobacco heating system THS is progressing rapidly, with reduced risks compared to smoking.

Our research on the latest smoke-free alternative product, Tobacco Heating System (THS) 1, is rapidly advancing. They support the following investigation results (based on expected usage):

 

THS does not produce combustion or smoke. According to laboratory tests, harmful and potentially harmful constituents (HPHCs) in THS aerosol are, on average, 95% lower in toxicity than cigarette smoke. Indoor air quality tests also show that THS aerosol does not have an adverse impact on indoor air quality and it is not a source of second-hand smoke. A 90-day study conducted in the US and a 90-day study conducted in Japan reported that adult smokers who switched exclusively to THS significantly reduced their exposure to selected HPHCs (based on measures of biomarkers of exposure). The level of reduction in biomarkers of exposure was comparable to that of smokers who quit during the study period. Of course, the best option is always to quit smoking and nicotine altogether. Clinical results from a 6-month biomarkers of potential harm study suggest that switching exclusively to THS may have a positive impact on the health of adult smokers. Our research indicates that non-smokers or former smokers have little interest in THS. 70% of adult smokers who switch to THS use it exclusively or in combination with other smokeless products. Teeth staining from THS aerosol is significantly lower than that of cigarette smoke. To date, all of our studies indicate that THS poses a smaller risk of harm compared to adult smokers who exclusively switch to it, although there may still be some risk.

 

Original link: We cannot provide a translation for this text as it does not contain any identifiable language.

 

Research investigation into tobacco heating systems

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI’s U.S. business released a white paper and cited a national online survey showing that 79.00% of Americans surveyed believe more should be done to reduce smoking-related harm. The paper calls on policymakers, public health authorities, and medical professionals to place cigarette smoking back at the center of public health priorities, and recommends broader access to FDA-authorized smoke-free alternatives, clearer nicotine risk communication, and risk-based taxation.
Apr.15 by 2FIRSTS.ai
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
Philip Morris Korea to Launch IQOS Iluma i One “Electric Purple” Color, Expanding Into Major Convenience Store Channels From May
Philip Morris Korea to Launch IQOS Iluma i One “Electric Purple” Color, Expanding Into Major Convenience Store Channels From May
Philip Morris Korea said on March 31 that it will begin selling the new “Electric Purple” color for the heated tobacco device IQOS Iluma i One at major convenience stores nationwide in South Korea starting May 2. The color will first be introduced on April 10 at the official IQOS online store and nine IQOS directly operated stores nationwide. To mark the expansion of its sales channels, the company will run promotions at major convenience stores through May 20.
Mar.31
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
From May 8 to 10, 2026, Mylor (Booth E70) will exhibit at The Vaper Expo UK, where it will showcase its systematic experience design solutions for e-liquids. At present, the e-liquid market commonly faces a challenge: many products have “no obvious shortcomings, but lack memorable features.” In response, Mylor has proposed refined solutions across multiple dimensions, including device-adaptive sweetness, progressive cooling sensation, fruit-oriented sourness, and segmented nicotine experience.
May.08